Financing ·
PTC Therapeutics, Inc. priced a $500.0 million offering of 0.00% Convertible Senior Notes due 2031, with an option for…
PTCTPtc Therapeutics, Inc.
PTC Therapeutics, Inc. priced a $500.0 million offering of 0.00% Convertible Senior Notes due 2031, with an option for initial purchasers to purchase an additional $50.0 million. The company expects to use $328.8 million of the net proceeds to repurchase $222.0 million of its outstanding 1.5% Convertible Senior Notes due 2026. PTC Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases.